According to ASCO guidelines, which factors should guide the regimen selection of adjuvant therapy for breast cancer?

Updated: May 21, 2019
  • Author: Erin V Newton, MD; Chief Editor: Neetu Radhakrishnan, MD  more...
  • Print


In 2016 the American Society for Clinical Oncology (ASCO) published guidelines, based on the Cancer Care Ontario Clinical Practice Guideline, for the selection of optimal adjuvant chemotherapy regimens for HER2-negative and HER2-positive breast cancers. [3]  The guidelines advised that treatment recommendations be guided by the following:

  • Risk of recurrence
  • Potential toxicities
  • Comorbidities
  • Overall likelihood of benefit  

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!